A recent study demonstrated that the loss of RBM39 induces splicing defects in key DNA damage repair genes, such as ATM and BRCA1, in ovarian cancer, leading to increased sensitivity to cisplatin and various PARPi18. This evidence concerns the gene BRCA1 and ovarian cancer.